News & Events

Impel NeuroPharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

SEATTLE, May 17, 2019 — Phase 1 Data Support Selection of Company’s Proprietary Formulation of Investigational Nasal Olanzapine, INP105, Currently Being Evaluated for Acute Agitation in Bipolar 1 and Schizophrenia

READ MORE

Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019…

READ MORE

Impel NeuroPharma Appoints Jennifer L. Berman as Vice President of Marketing

SEATTLE, February 19, 2019 — Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization. Impel NeuroPharma today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing.

READ MORE